Business & Leadership

Carey Advises Ingalfarma on Merger Deal with Level Bioscience

© Darko Stojanovic

Carey has advised Ingalfarma on the merger with Level Bioscience, a company that develops a line of research related to regulators of the immune response in oral health, with technology in process of being patented abroad. The merger was closed on December 1st.


Established in 2006, Ingalfarma is a Chilean national research laboratory that aims to develop solutions to oral pathologies which are difficult to treat.


This merger is one of the first between two Chilean companies to have begun life as startups and gone on to acquire traction in Chile and abroad.


Ingalfarma, responsible for continuing the business after this merger, is currently in the process of becoming an international company.


Carey, led by partner Francisco Guzmán and associate Nicolás Calderón, served as legal counsel to Ingalfarma. Andes IP acted as legal counsel to Level Bioscience.




Accenture's CEO and CFO interview by Leaders League Group

About us